Seth Loring Harrison - Nov 30, 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Director
Signature
/s/ Jonathan Young, attorney-in-fact
Stock symbol
AKRO
Transactions as of
Nov 30, 2022
Transactions value $
-$1,085,739
Form type
4
Date filed
12/2/2022, 04:48 PM
Previous filing
Nov 1, 2022
Next filing
Jun 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Sale -$294K -6.32K -4.29% $46.44 141K Nov 30, 2022 Direct F1
transaction AKRO Common Stock Sale -$228K -4.78K -3.39% $47.60 136K Nov 30, 2022 Direct F2
transaction AKRO Common Stock Sale -$318K -6.85K -4.28% $46.44 153K Nov 30, 2022 See Footnote F1, F3
transaction AKRO Common Stock Sale -$247K -5.18K -3.38% $47.60 148K Nov 30, 2022 See Footnote F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.28 to $47.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.29 to $47.93, inclusive.
F3 Represents shares held directly by Les Pommes, LLC, a family limited liability company for which the reporting person is the manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.